Format
Sort by

Send to

Choose Destination

Search results

Items: 1 to 20 of 142

1.

Budgetary Impact Analysis of Reimbursement Varenicline for the Smoking-Cessation Treatment in Patients with Cardiovascular Diseases, Chronic Obstructive Pulmonary Disease or Type-2 Diabetes Mellitus: A National Health System Perspective.

Cedillo S, Sicras-Mainar A, Jiménez-Ruiz CA, Fernández de Bobadilla J, Rejas-Gutiérrez J.

Eur Addict Res. 2016 Oct 29;23(1):7-18. [Epub ahead of print]

PMID:
27794567
2.

Use of healthcare resources and costs associated to the start of treatment with injectable drugs in patients with type 2 diabetes mellitus.

Sicras-Mainar A, Navarro-Artieda R, Morano R, Ruíz L.

Endocrinol Nutr. 2016 Dec;63(10):527-535. doi: 10.1016/j.endonu.2016.07.001. English, Spanish.

PMID:
27744013
3.

Cost of treatment of peripheral neuropathic pain with pregabalin or gabapentin in routine clinical practice: impact of their loss of exclusivity.

Sicras-Mainar A, Rejas-Gutiérrez J, Pérez-Páramo M, Navarro-Artieda R.

J Eval Clin Pract. 2016 Sep 27. doi: 10.1111/jep.12634. [Epub ahead of print]

PMID:
27671223
4.

[A retrospective, observational and multicentre study on patients with hyperactive bladder on treatment with mirabegron and oxybutinine under usual clinical practice conditions].

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, Saez M, Coll-de Tuero G, Sánchez L.

Semergen. 2016 Jun 28. pii: S1138-3593(16)30092-2. doi: 10.1016/j.semerg.2016.05.006. [Epub ahead of print] Spanish.

PMID:
27371430
5.

Clinical and economic consequences of treating patients with peripheral neuropathic pain with brand name or generic drugs in routine clinical practice: The effects of age and sex.

Navarro-Artieda R, Rejas-Gutiérrez J, Pérez-Paramo M, Sicras-Mainar A.

Neurologia. 2016 Jun 16. pii: S0213-4853(16)30043-3. doi: 10.1016/j.nrl.2016.03.012. [Epub ahead of print] English, Spanish.

6.

[Clinical characteristics and treatment response in adult patients with non-Hodgkin's chronic lymphocytic leukemia (CLL)].

Sicras-Mainar A, Castro A, Navarro-Artieda R.

Gac Med Mex. 2016 Jan-Feb;152(1):59-69. Spanish.

7.

Use of antidepressants in the treatment of major depressive disorder in primary care during a period of economic crisis.

Sicras-Mainar A, Navarro-Artieda R.

Neuropsychiatr Dis Treat. 2015 Dec 30;12:29-40. doi: 10.2147/NDT.S91227.

8.

Persistence and concomitant medication in patients with overactive bladder treated with antimuscarinic agents in primary care. An observational baseline study.

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, Sáez-Zafra M, Coll-de Tuero G.

Actas Urol Esp. 2016 Mar;40(2):96-101. doi: 10.1016/j.acuro.2015.09.004. English, Spanish.

PMID:
26556482
9.

Adherence and Persistence In Patients Initiating Treatment With Injectable Therapies for Type 2 Diabetes Mellitus (T2dm) In Spain.

Sicras-Mainar A, Navarro R, Ruiz L, Morano R.

Value Health. 2015 Nov;18(7):A612. doi: 10.1016/j.jval.2015.09.2122. No abstract available.

10.

Identification of Factors Involved In Medication Compliance: Incorrect Inhaler Technique of Asthma Treatment Leads to Poor Compliance.

Darba J, Ramírez G, Sicras-Mainar A, Garcia-Bujalance L, Torvinen S, Sánchez-de la Rosa R.

Value Health. 2015 Nov;18(7):A362-3. doi: 10.1016/j.jval.2015.09.706. No abstract available.

11.

The Importance of Inhaler Devices: An Incorrect Inhaler Technique Leads to Suboptimal Medication Compliance In Patients With Copd.

Darba J, Ramírez G, Sicras-Mainar A, Francoli-Martínez P, Torvinen S, Sánchez-de la Rosa R.

Value Health. 2015 Nov;18(7):A362. doi: 10.1016/j.jval.2015.09.703. No abstract available.

12.

Device Inhalators In Asthma and Their Impact on Treatment Adherence.

Sicras-Mainar A, Collar JM, Ferrer V, Navarro R.

Value Health. 2015 Nov;18(7):A362. doi: 10.1016/j.jval.2015.09.704. No abstract available.

13.

Copd Ics/Laba Treatment Inhalers and Their Impact on Adherence.

Sicras-Mainar A, Ferrer V, Navarro R, Collar JM.

Value Health. 2015 Nov;18(7):A362. doi: 10.1016/j.jval.2015.09.702. No abstract available.

14.

Impact of Loss of Work Productivity in Patients with Overactive Bladder Treated with Antimuscarinics in Spain: Study in Routine Clinical Practice Conditions.

Sicras-Mainar A, Navarro-Artieda R, Ruiz-Torrejón A, Sáez-Zafra M, Coll-de Tuero G.

Clin Drug Investig. 2015 Dec;35(12):795-805. doi: 10.1007/s40261-015-0342-2.

PMID:
26464261
15.

Costs of ulcerative colitis from a societal perspective in a regional health care area in Spain: A database study.

Aldeguer X, Sicras-Mainar A.

Gastroenterol Hepatol. 2016 Jan;39(1):9-19. doi: 10.1016/j.gastrohep.2015.04.007.

PMID:
26211705
16.

Comparative effectiveness and costs of generic and brand-name gabapentin and venlafaxine in patients with neuropathic pain or generalized anxiety disorder in Spain.

Sicras-Mainar A, Rejas-Gutiérrez J, Navarro-Artieda R.

Clinicoecon Outcomes Res. 2015 Jun 4;7:299-312. doi: 10.2147/CEOR.S85756.

17.

Response: economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients (diabetes metab j 2015;39:74-81).

Sicras-Mainar A, Navarro-Artieda R.

Diabetes Metab J. 2015 Apr;39(2):173-4. doi: 10.4093/dmj.2015.39.2.173. No abstract available.

18.

Economic impact of combining metformin with dipeptidyl peptidase-4 inhibitors in diabetic patients with renal impairment in spanish patients.

Sicras-Mainar A, Navarro-Artieda R.

Diabetes Metab J. 2015 Feb;39(1):74-81. doi: 10.4093/dmj.2015.39.1.74.

19.

[Combination therapy of metformin vs dipeptidulpeptidase inhibitors and sulfonylureas in type 2 diabetes: clinical and economic impact].

Sicras-Mainar A, Navarro-Artieda R.

Rev Peru Med Exp Salud Publica. 2014 Oct-Dec;31(4):626-34. Spanish.

20.

Prevalence of metabolic syndrome according to the presence of negative symptoms in patients with schizophrenia.

Sicras-Mainar A, Maurino J, Ruiz-Beato E, Navarro-Artieda R.

Neuropsychiatr Dis Treat. 2014 Dec 30;11:51-7. doi: 10.2147/NDT.S75449.

Items per page

Supplemental Content

Loading ...
Support Center